|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
After GSK's move last week, Pfizer also said it is making more spending cuts, which is expected to deliver about $1.5 billion in additional savings, particularly on manufacturing. You can check out the details here, and our broader coverage on the company's cost-cutting plans here. |
|
|
|
Reynald Castaneda |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Anna Brown
|
WuXi AppTec, the Chinese contract manufacturer under scrutiny from the Pentagon, isn't slowing down. For the first time, the company appears to have generated more... | |
|
|
|
 |
|
President Donald Trump signs an executive order for tariffs, April 2, 2025 (Andrew Leyden/NurPhoto via AP Images) |
|
|
|
by Anna Brown
|
Over the past 16 months, the Trump administration’s pharma tariffs have loomed large over the industry. While the first wave of these levies was scheduled... | |
|
|
|
 |
|
Fujifilm Biotechnologies president Maja Pedersen (L) and strategy advisor Lars Petersen |
|
|
|
by Anna Brown
|
Lars Petersen has stepped down from his role as CEO and president at Fujifilm Biotechnologies effective immediately, and COO Maja Pedersen is taking the wheel... | |
|
|
|
|
|
|
by Ayisha Sharma
|
Merck KGaA said it expects to receive tariff refunds for its life science business through the end of 2026 after the US Supreme Court blocked... | |
|
|
|
|
|
|
by Max Bayer
|
Pfizer announced $2.5 billion in cost cuts, taking another step in a post-Covid strategy that has been defined by mid-sized dealmaking and constant expense trimming... | |
|
|
|
|
|
|
by Max Bayer
|
One of the most closely watched commercial drug races is now off and running, after Takeda snagged FDA approval of its orexin agonist to treat... | |
|
|
|
|
|
|
by Kyle LaHucik
|
Eli Lilly posted $23 billion in second-quarter revenues, coming in about $3 billion above analysts' estimates. |
|
|
